| Document and Entity Information | Apr. 08, 2024 |
| Document Information [Line Items] | |
| Entity Registrant Name | Prelude Therapeutics Incorporated |
| Amendment Flag | true |
| Amendment Description | Explanatory NoteOn April 10, 2024, Prelude Therapeutics Incorporated (the “Company”) filed a Current Report on Form 8-K (the “Original Report”) with the Securities and Exchange Commission to, among other things, report under Item 5.02 thereof the appointment of Bryant D. Lim as Interim Chief Financial Officer of the Company.This Amendment No. 1 on Form 8-K/A (“Amendment No. 1”) amends the Original Report to add the information required by Item 5.02(c)(3) of Form 8-K, which was unavailable at the time the Original Report was filed. No other amendments to the Original Report are being made by this Amendment No. 1. |
| Entity Central Index Key | 0001678660 |
| Document Type | 8-K/A |
| Document Period End Date | Apr. 08, 2024 |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-39527 |
| Entity Tax Identification Number | 81-1384762 |
| Entity Address, Address Line One | 175 Innovation Boulevard |
| Entity Address, City or Town | Wilmington |
| Entity Address, State or Province | DE |
| Entity Address, Postal Zip Code | 19805 |
| City Area Code | (302) |
| Local Phone Number | 467-1280 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, $0.0001 par value per share |
| Trading Symbol | PRLD |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
